CA2955386C - Traitement du cancer au moyen d'un recepteur d'antigene chimerique anti-bcma humanise - Google Patents

Traitement du cancer au moyen d'un recepteur d'antigene chimerique anti-bcma humanise

Info

Publication number
CA2955386C
CA2955386C CA2955386A CA2955386A CA2955386C CA 2955386 C CA2955386 C CA 2955386C CA 2955386 A CA2955386 A CA 2955386A CA 2955386 A CA2955386 A CA 2955386A CA 2955386 C CA2955386 C CA 2955386C
Authority
CA
Canada
Prior art keywords
seq
acid sequence
amino acid
bcma
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2955386A
Other languages
English (en)
Other versions
CA2955386A1 (fr
Inventor
Jennifer Brogdon
Eugene Choi
Hilmar Ebersbach
David Glass
Heather Huet
Carl H. June
Joan Mannick
Michael C. Milone
Leon Murphy
Gabriela Plesa
Celeste Richardson
Marco Ruella
Reshma Singh
Yongqiang Wang
Qilong Wu
Original Assignee
Novartis AG
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG, University of Pennsylvania Penn filed Critical Novartis AG
Priority claimed from PCT/US2015/041378 external-priority patent/WO2016014565A2/fr
Publication of CA2955386A1 publication Critical patent/CA2955386A1/fr
Application granted granted Critical
Publication of CA2955386C publication Critical patent/CA2955386C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

L'invention concerne des compositions et des méthodes de traitement de maladies associées à BCMA. Elle concerne également un récepteur d'antigène chimérique (CAR) spécifique de vecteurs BCMA codant ce dernier et des lymphocytes T de recombinaison comprenant le BCMA CAR. Cette invention porte en outre sur des méthodes d'administration d'un lymphocyte T génétiquement modifié exprimant un CAR qui présente un domaine de liaison BCMA.
CA2955386A 2014-07-21 2015-07-21 Traitement du cancer au moyen d'un recepteur d'antigene chimerique anti-bcma humanise Active CA2955386C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2014/082586 2014-07-21
CN2014082586 2014-07-21
CNPCT/CN2014/090501 2014-11-06
CN2014090501 2014-11-06
PCT/US2015/041378 WO2016014565A2 (fr) 2014-07-21 2015-07-21 Traitement du cancer au moyen d'un récepteur d'antigène chimérique anti-bcma humanisé

Publications (2)

Publication Number Publication Date
CA2955386A1 CA2955386A1 (fr) 2016-01-28
CA2955386C true CA2955386C (fr) 2025-12-16

Family

ID=

Similar Documents

Publication Publication Date Title
US12214037B2 (en) Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
US11952428B2 (en) BCMA chimeric antigen receptors and uses thereof
AU2021203790B2 (en) Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
AU2015292811B2 (en) Treatment of cancer using a CLL-1 chimeric antigen receptor
AU2015305531B2 (en) Anti-CD123 chimeric antigen receptor (CAR) for use in cancer treatment
US20200055948A1 (en) Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
AU2021200929A1 (en) Treatment of cancer using a CD33 chimeric antigen receptor
CA2955386C (fr) Traitement du cancer au moyen d'un recepteur d'antigene chimerique anti-bcma humanise